To Assess the Anti-anginal Safety and Efficacy of Ivabradine in Subjects With Stable，Symptomatic Chronic Angina
NCT ID: NCT02623569
Last Updated: 2015-12-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
336 participants
INTERVENTIONAL
2014-10-31
2017-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Experimental: Ivabradine Ivabradine 5 mg twice a day for first 4 weeks and 7.5mg twice a day when positive ETT and HR\>60times/min or negative ETT and HR\>80times/min of subjects.
Active Comparator: Atenolol Atenolol 12.5 mg twice a day for first 4 weeks and 25mg twice a day when positive ETT and heard rate\>60times/min or negative ETT and HR \>80times/min of subjects.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
2. Treatment period：Patients carried out ETT after therapy with Ivabradine(5mg,bid)/ Atenolol(12.5mg,bid) for 4 weeks.The dose adjust base on test result and heart rate, Ivabradine(5mg,bid)/Atenolol(12.5mg,bid) or Ivabradine(7.5mg,bid)/ Atenolol(25mg,bid) for 8 weeks and carried out ETT.
3. security period：After the treatment period, all patients to take Atenolol 12.5mg/ 25mg bid 1 week.
If heart rate are low 50 times/min after taking Ivabradine 5mg/ Atenolol 12.5mg, subjects should withdrawal and dropped out study. If subjects heart rate are low 50 times/min after taking Ivabradine 7.5mg/ Atenolol 25mg, subjects should change the dose to Ivabradine 5mg/ Atenolol 12.5mg.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ivabradine
Ivabradine 5 mg twice a day for first 4 weeks and 7.5mg twice a day when positive ETT and HR（heard rate）\>60times/min or negative ETT and HR（heard rate）\>80times/min of subjects.
Ivabradine
Not Provided
Atenolol
Atenolol 12.5 mg twice a day for first 4 weeks and 25mg twice a day when positive ETT and HR（heard rate）\>60times/min or negative ETT and HR （heard rate）\>80times/min of subjects.
Atenolol
Not Provided
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ivabradine
Not Provided
Atenolol
Not Provided
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Clearly understand the study and participate in it voluntarily; the informed consent should be signed in person or by legal guardian.
3. Chronic Stable Angina was confirmed by clinic over 3 months.
4. Patients with clinical diagnosis of chronic stable angina and must meet one of the following conditions:
* Patients who have a history of myocardial infarction over 3 months.
* Patients who have received coronary intervention or CABG（Coronary Artery Bypass Grafting） over 6 months.
* Stenosis of more than 50% in at least one major epicardial coronary artery shown by Coronary Angiograph.
* Ischemic electrocardiogram changes：ST-segment depression ≥ 1.0 mm compared with P-R or elevate≥1.0 mm during exercise ECG Computed Tomography Angiography (CTA) showed more than 50% stenosis with typical angina symptoms
5. ultrasonic cardiogram disclosed that left ventricular ejection fraction ≥50 %.
6. Patients who manifested positive ETT (exercise tolerance testing) (defined as ST-segment depression ≥ 1 mm compared with at rest, with or without limiting angina) at screening.
Exclusion Criteria
2. Patients with myocardial infarction within the preceding 3 months
3. Patients have received Coronary angioplasty or CABG within the preceding 6 months.
4. Patients who have severity vessels disease with left main coronary artery but have no valid treatment.
5. Patients with congestive heart failure(New York Heart Association class III or IV)or acute pulmonary edema.
6. Patients whose rest heart rate\< 60 bpm.
7. Patients with nonrespiratory sinus arrhythmia or arrhythmia(e.g.,AVB(auriculo-ventricular block)ⅡⅢ,atrial fibrillation,atrial flutter,SSS(sick sinus syndrome)) or implantable cardiac defibrillator (ICD).
8. Patient with any conditions that interfered the performance of exercise tolerance test or a history of an abnormal exercise response limited by electrocardiograph (ECG) changes.
9. Patient with uncontrolled hypertension (seated systolic blood pressure (SBP）≥180 mmHg or diastolic blood pressure (DBP) ≥100 mmHg); SBP\<90 mmHg and/or DBP\<60 mmHg
10. Diabetic with uncontrolled blood glucose(FBG≥11.1 mmol/L and/or RBG≥13.6 mmol/L）
11. Patients with anemia(male:Hb≤120 g/L；female：Hb≤110 g/L)
12. Patients complicated with systemic diseases included thyroid dysfunction、glaucoma、cataract，neurological、mental、psychological disease and any other disease that influence the judgment.
13. Severe concurrent pathology, including terminal illness (cancer, AIDS, etc.).
14. Patients with mental or legal disorder.
15. Patients who were suspected addicted into alcohol or drug abuse or with severe complications that would make the condition more complicated assessed by the investigator.
16. People have liver or renal dysfunction (ALT≥2×ULN、AST≥2×ULN、eGFR≤60ml/min/1.73m2）
17. Patients who should use unapproved drug during the study.
18. Patients who accepted amiodarone(in recent 3 months)and/or benzetimide、βblockers（in recent 7 days)、
19. Patients with history of allergy or suspected allergic to the drug（e.g.，Hydrochloric ivabradine,atenolol, βblockers）or lactose.
20. Woman who disagree with contraception during treatment period ，with pregnancy, lactation or positive result of pregnancy test.
21. Patients with Chronic Obstructive Pulmonary Disease (COPD) requiring bronchodilators.
22. Patients who is participating in other trials or has been participated in other trials in recent 3 months
23. Patients who were unable to participate in the study as judged by investigator.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Xintong Pharmacy Company
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Guizhou Provincial People's Hospital
Guiyang, Guizhou, China
Zhongda Hospital Southeast University
Nanjing, Jiangsu, China
The General Hospital of Shenyang Military
Shenyang, Liaoning, China
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A130901CSPF01
Identifier Type: -
Identifier Source: org_study_id